Liu Hongzhou, Xu Ying, Peng Jie
School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, People's Republic of China.
Neuropsychiatr Dis Treat. 2023 Jan 7;19:97-107. doi: 10.2147/NDT.S376942. eCollection 2023.
genes were reported to be involved in susceptibility to mental disorder. The results between deletions of genes and schizophrenia were inconclusive and confusing. Therefore, we performed this updated meta-analysis to outline the association using a new method for quality assessment.
Sixteen reported studies were selected, and the overall OR and 95% CI were calculated and analyzed by Review Manager 5.4 and STATE 12. The Newcastle-Ottawa Quality Assessment Scale (NOS) for case-control studies was rewritten to evaluate the quality of published studies, as there was no "Exposure" in these studies and other factors should be suggested to assess the quality.
There was no significant association between deletions of genes and SZ risk ( > 0.05 in Random model). We also failed to find a significant relation between null genotypes and SZ risk in East Asian population. Based on further analysis of PCR methods, null was weakly associated with SZ risk in 8 studies using multiplex PCR (OR = 1.17, 95% CI = 1.00-1.37, = 0.05), but null was a protective factor for SZ risk (OR = 0.73, 95% CI = 0.56-0.94, = 0.02). When stratified by rewritten NOS stars and deductions, null was significantly associated with SZ risk in 9 studies with high quality (OR = 1.24, 95% CI = 1.08-1.43, = 0.002), and in 10 studies with no deductions (OR = 1.20, 95% CI = 1.05-1.38, = 0.007).
null genotype may be a genetic risk factor for SZ in studies using multiplex PCR and high-quality studies. However, null might be a protective factor. Besides, we provided a new method for quality assessment and it was useful and should be promoted in further analysis.
有报道称基因与精神障碍易感性有关。基因缺失与精神分裂症之间的结果尚无定论且令人困惑。因此,我们进行了这项更新的荟萃分析,以使用一种新的质量评估方法概述两者之间的关联。
选取了16项已报道的研究,通过Review Manager 5.4和STATE 12计算并分析总体比值比(OR)和95%置信区间(CI)。由于这些研究中没有“暴露”情况,且应建议其他因素来评估质量,因此重写了病例对照研究的纽卡斯尔-渥太华质量评估量表(NOS),以评估已发表研究的质量。
基因缺失与精神分裂症风险之间无显著关联(随机模型中P>0.05)。我们在东亚人群中也未发现无效基因型与精神分裂症风险之间存在显著关系。基于对聚合酶链反应(PCR)方法的进一步分析,在8项使用多重PCR的研究中,无效与精神分裂症风险弱相关(OR = 1.17,95%CI = 1.00 - 1.37,P = 0.05),但无效是精神分裂症风险的保护因素(OR = 0.73,95%CI = 0.56 - 0.94,P = 0.02)。当按重写的NOS星级和扣分进行分层时,在9项高质量研究中无效与精神分裂症风险显著相关(OR = 1.24,95%CI = 1.08 - 1.43,P = 0.002),在10项无扣分的研究中也显著相关(OR = 1.20,95%CI = 1.05 - 1.38,P = 0.007)。
在使用多重PCR的研究和高质量研究中,无效基因型可能是精神分裂症的遗传风险因素。然而,无效可能是一个保护因素。此外,我们提供了一种新的质量评估方法,它很有用,应在进一步分析中推广。